Dr. George Siber is an infectious disease trained physician with 40 years’ experience in developing vaccines and antibody products. Dr. George Siber was an Associate Professor of Dana Farber Cancer Institute at Harvard Medical School and Director of the Massachusetts Public Health Biologic Laboratories. Currently he is an Adjunct Professor of Medicine at Johns Hopkins Medical School.Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (Pfizer) 1996-2007, leading the development and approval of multiple childhood vaccines including Prevenar 7 and 13.Currently Dr. Siber is a Co-founder and Board Member of Affinivax and a Board Member of Genocea Biosciences and serves on multiple Scientific Advisory Boards including AdVaccine, Everest, Clover, ILiAD, Valneva, Vaxart and Vaxxinity. Dr. Siber has received multiple awards including the Albert Sabin Gold Medal in vaccinology in 2016.
Prof. Liming Li is the Boya Professor and the Dean of School of Public Health and major Epidemic Prevention and Control, Peking University. The Founder Director General of Chinese Center for Disease Control and Prevention (CDC).Prof. Li has been engaged in the large population cohort study, chronic disease epidemiology, and geriatric epidemiology for a long time. Prof. Li was awarded the EISENHOWER Fellowship Award in 1997; the Johns Hopkins Society of Scholars Award in 2006; Honorary Fellow of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom (HonFFPH) in 2010 and Academician of International Eurasian Academy of Sciences (IEAS) in 2017.Over 450 publications in peer-reviewed journals
Dr. Luis Barreto is the President of Dr. Luis Barreto & Associates. Dr Barreto is a member of the International Advisory Board of the McMaster/Maastricht/Manipal Global Health Program, a member of the Scientific Advisory Board for the Human Health Therapeutics Group of the National Research Council (NRC), Canada, a Senior Scientifc Advisor to Inventprise/InventVac U.S./Canada. Dr. Barreto was formerly Vice-President of Clinical, Medical and Regulatory Affairs, Vice-President of Immunization and Science Policy, and a member of the Senior Management Team at Sanofi Pasteur Canada, as well as a member of its Global Public Policy group. He spent more than 23 years in research and development, leading Phase 1-IV clinical trials, licensing and launching vaccines globally. Dr. Barreto has been/is on many volunteer boards of directors, including VIDO-InterVAC (Chair), Research Canada, March of Dimes. He has been/is on many advisory review panels for the Tri Council (CIHR, NSERC and CFI) with the government of Canada and Not for Profit organisations. He has also been member of two panels of the Council of Canadian Academies, Canada.
Prof. David Briles is a renowned expert on protein-based Pneumococcal vaccines. He used to be a professor of microbiology at the University of Alabama Birmingham (UAB), focusing on the molecular biology and genetics of bacterial pathogenesis, bacterial vaccines, and epidemiology of bacterial pneumococcal and typhoid infection in mice infections. Over the past 30 years he has focused on protein virulence factors of pneumococci, their mechanisms of action and use in vaccines. Prof. Briles and his team were awarded over 30 patents and published over 99 primary papers on pneumococcal vaccine antigens. Dr. Briles’ lab was the first to show that non-capsule antigens could elicit protective immunity in mice against pneumococcal infection. His lab’s pneumococcal PSPA antigen has been shown to elicit protective antibody in humans. Prof. Briles served as a main participant on study sections at the NIH and FDA. He has served on editorial boards and as an advisor to the WHO, PAHO, FDA, and the PATH foundation.
Prof. Dr. Pierre Van Damme obtained his PhD in epidemiology and public health in 1994. He was for more than 35 years active in vaccine, clinical trial and infectious disease research. Since 2000 he is full professor in Vaccinology at the University of Antwerp, Faculty of Medicine and Health Sciences. Dr. Van Damme is the founder and director of the Centre for the Evaluation of Vaccination (CEV, University of Antwerp), a WHO Collaborating Centre for the control and prevention of infectious diseases in European region. Dr. Van Damme has been for more than 25 years a regular advisor for national and international organizations, including the National Immunization Technical Advisory Group, and the World Health Organization. He has been appointed as chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE) (2005-2015).
Prof. Shan Lu is a physician scientist with research interest in novel vaccine and antibody development, an expert on vaccines for HIV, influenza, biodefense agents, and emerging infectious diseases. Dr. Lu was the past president and a current Executive Board member for the International Society for Vaccines (ISV). Prof. Lu is known as the originator of the DNA prime/protein boost approach to vaccination. He is one of the few people to have developed a candidate vaccine starting at the bench and going all the way to a clinical trial in humans.Prof. Lu is the editor-in-chief of Emerging Microbes & Infections.
Prof. David Salisbury was Director of Immunisation at the Department of Health and has chaired the Strategic Advisory Group of Experts on immunisation for the World Health Organisation. He has led the introduction of a large number of new immunisation programmes and vaccines. The UK immunisation programme is one of the foremost in the world and its excellence is recognised in both developed and developing countries. He has demonstrated that the successful immunisation programmes require the collaboration of science, policy development, strategy and implementation, and whose impact has been the saving of thousands of lives. He is the Chair of the Jenner Vaccine Foundation and is a Board Trustee of the Sabin Vaccine Institute. He is also Chair of the WHO Global Commission for Certification of Poliomyelitis Eradication.
Prof. Jingren Zhang is the professor of Medical School in Tsinghua university, mainly focusing on the molecular mechanism of acute pneumonia and related diseases. Dr. Zhang obtained his doctorate in microbiology from the University of Texas Health Science Center-Houston in 1997. During 1998 to 2000, he worked as a postdoctoral fellow in the department of infectious diseases at St. Jude Children’s Research Hospital. Dr. Zhang worked in the China Agricultural University, associate professor from Albany Medical College, US and a visiting professor by institute of microbiology, Chinese Academy of Sciences.